engene, inc

enGene Inc. is a biotechnology company developing a robust, proprietary non-viral vector platform to deliver genes to mucosal cells lining the gut. The vector system can be administered to the intestine via the oral or enema route. enGene is developing its unique gut-optimized gene delivery formulation into an orally available Gene Pill, which has the potential to be a platform for oral delivery of a wide range of protein drugs. Its primary focus is targeting its technology to enable localized delivery of immune-modulating proteins to the gut for treating various immune disorders. With its exciting cutting edge technology, enGene successfully established alliances with two of the worlds top ten largest pharmaceutical companies: Janssen Biotech and Takeda Pharmaceutical. enGene is also supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.